The results indicated that the SETD2 gene may be involved in the androgen receptor response pathway of prostate cancer, and that the SETD2 gene mutations have a potential role in the occurrence and development of castration-resistant prostate cancer (CRPC). This evidence concerns the gene SETD2 and Familial prostate cancer.